Myeloma is a rare cancer primarily affecting older adults, characterised by malignant plasma cells. Symptoms include high calcium levels and renal failure. Treatment has evolved from radiation to modern therapies like immunomodulators and monoclonal antibodies. BCMA is a key receptor on plasma cells, and therapies targeting BCMA show promise. The talk discusses various BCMA-targeted therapies, their effectiveness, and future directions for improving patient outcomes.